Table 1.
Tumor types and chemotherapy regimens used by cohort for participants in this study
| Cancer type | Chemotherapy regimen | Disease state |
|---|---|---|
| 24 h cohort | ||
| Urothelial | Gemcitabine + Cisplatin | Metastatic |
| Urothelial | Gemcitabine + Cisplatin | Adjuvant |
| NSCLC | Gemcitabine + Cisplatin | Metastatic |
| Urothelial | Gemcitabine + Cisplatin | Neoadjuvant |
| Ovarian | Carboplatin + Paclitaxel | Adjuvant |
| Uterine | Carboplatin + nab-Paclitaxel | Metastatic |
| 48 h cohort | ||
| Ovarian | Carboplatin + Paclitaxel | Adjuvant |
| Breast | TCH | Adjuvant |
| Breast | TCH | Adjuvant |
| Breast | TCH | Adjuvant |
| Urothelial | Gemcitabine + Cisplatin | Neoadjuvant |
| Breast | TCH | Adjuvant |
| Ovarian | Carboplatin + Paclitaxel | Metastatic |
| 72 h cohort | ||
| Ovarian | Carboplatin + Paclitaxel | Metastatic |
| Urotheliala | Gemcitabine + Cisplatin | Neoadjuvant |
| Uterine | Carboplatin + Paclitaxel | Adjuvant |
| Breast | TCH | Neoadjuvant |
| Urothelial | Gemcitabine + Cisplatin | Neoadjuvant |
| Ovarian | Carboplatin + Paclitaxel | Adjuvant |
| Ovarian | Carboplatin + Paclitaxel | Metastatic |
TCH Docetaxel, carboplatin, trastuzumab
aThis patient was ineligible due to BMI 20.1 (original protocol required ≥20.5 but the protocol was subsequently amended to allow patients with normal BMI ≥18.5 given a lack of weight loss observed in the first 2 cohorts) and the data were included from 2 successful fasting cycles